BBIO
BridgeBio Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$76.82
+3.77%Next report
Analyst consensus
- Next report date
- Feb 23, 2027
- EPS estimate
- -$0.58
- Revenue estimate
- $310.8M
Latest reported
- Last report date
- Oct 29, 2026
- EPS actual
- -$0.42
- EPS estimate
- -$0.54
- Revenue actual
- $353.2M
- Revenue estimate
- $293.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 9
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -16.6%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $110
- PT range
- $88 – $156
- Analysts
- 12
11 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 29, 2026 | -$0.54 | -$0.42 | Beat 22.54% | $353.2M |
| Aug 10, 2026 | -$0.58 | -$0.78 | Miss -35.52% | $243.7M |
| May 7, 2026 | -$0.70 | -$0.84 | Miss -20.00% | $194.5M |
| Feb 24, 2026 | -$0.75 | -$1.00 | Miss -33.33% | $154.2M |
| Oct 29, 2025 | -$0.88 | -$0.95 | Miss -7.95% | $120.7M |
| Feb 20, 2025 | -$1.09 | -$1.31 | Miss -20.18% | $5.9M |
| Aug 1, 2024 | -$1.09 | -$1.02 | Beat 6.42% | $2.2M |
| May 2, 2024 | -$0.40 | -$0.05 | Beat 87.50% | $211.1M |
| Feb 22, 2024 | -$0.95 | -$0.96 | Miss -1.05% | $1.7M |
| Nov 2, 2023 | -$0.86 | -$1.08 | Miss -25.58% | $4.1M |
| Aug 3, 2023 | -$0.86 | -$0.98 | Miss -13.95% | $1.6M |
| May 4, 2023 | -$0.84 | -$0.92 | Miss -9.52% | $1.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 23, 2027